Global Scales for Cognitive Screening in Parkinson's Disease: Critique and Recommendations
Movement Disorders
Skorvanek, M., Goldman, J. G., et al. (2018).
Movement Disorders, 33(2), 208-218.
This is a guideline providing recommendations on cognitive rating scales to measure global cognitive performance in Parkinson's Disease.
International Parkinson and Movement Disorder Society
<div>The following cognitive screening scales were Suggested for use in individuals with Parkinson's Disease:</div>
<ul>
<li>Alzheimer’s Disease Assessment Scale – Cognition (ADAS-COG)</li>
<li>Cambridge Cognitive Assessment – Revised (CAMCOG-R)</li>
<li>Mini-Mental State Examination (MMSE)</li>
<li>Parkinson Neurophsychiatric Dementia Assessment (PANDA)</li>
<li>Parkinson’s Disease Dementia – Short Screen (PDD-SS)</li>
<li>Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)</li>
</ul>
<div>“The SCOPA-COG [Scales for Outcomes of Parkinson’s Disease-Cognition] is suitable for screening, severity, and correlative studies. It is not recommended for treatment trials, unless more evidence on sensitivity to change is available” (Recommended with Caveats; p. 214).<br><br>“Strengths of the scale include its relatively short administration time, coverage of several cognitive domains, good reliability and predictive validity, and good psychometric properties, including lack of floor and ceiling effects” (p. 214).</div>
<div>“The MMP [Mini-Mental Parkinson] is suitable for screening and epidemiology studies in [Parkinson’s Disease], but not suitable for treatment trials because responsiveness has not been tested properly” (Recommended with Caveats; p. 214).<br><br>The MMP’s strengths included ease of administration and acceptable clinimetrics to identify early cognitive impairment. The MMP’s sensitivity ranged from 0.51 to 1 and its specificity ranged from 0.7 to 0.97.</div>
<div>The Short Portable Mental Status Questionnaire (SPSMQ) did not meet the criteria to be recommended or suggested for used in individuals with Parkinson's Disease (Listed).</div>
<div>The Mattis Dementia Rating Scale- Second Edition was found suitable for treatment trials and severity/correlation studies but was deemed unsuitable for screening in clinical practice and large population studies due to its lengthy time to administer (Recommended).<br><br>“Strengths include the good clinimetric properties of the scale, which is suitable for most levels of cognitive impairment and most types of dementia….” (p. 210).</div>
<div>The Parkinson’s Disease-Cognitive Rating Scale (PD-CRS) was deemed useful for all types of studies such as screening, prevalence, correlation, and treatment trials (Recommended).<br><br>“The PD-CRS is a sensitive screening measure covering several cognitive domains, has high reliability and responsiveness, and is very sensitive and specific for detection of [Parkinson’s Disease dementia] and reasonably sensitive and specific for Parkinson’s Disease mild cognitive impairment]” (p. 213).</div>
<div>The Montreal Cognitive Assessment (MoCA) was deemed suitable for screening in clinical practice and various research studies, such as prevalence studies and treatment trials (Recommended).<br><br>The MoCA’s strengths included relatively short administration time, assessment of a broad range of cognitive domains, and is sensitive to milder cognitive deficits in Parkinson’s Disease. The MoCA’s sensitivity ranged from 81% to 90% and its specificity ranged from 75% to 95%.</div>
